Study: A subset of patients with localized prostate cancer may benefit from immunotherapies
Study: A subset of patients with localized prostate cancer may benefit from immunotherapies In recent years, cancer immunotherapy has been effective in treating patients with immunogenic, or so-called "hot" tumors with increased levels of inflammation and the presence of immune cells in and around the tumors. Prostate cancer, however, is considered a "cold" tumor, with few immune cells recognizing and infiltrating prostate malignancies. Accordingly, prostate cancer has been found to respond poorly to the class of immunotherapies known as immune checkpoint inhibitors. In previous work, a team ...
Source: news-medical.net